Impact Therapeutics, Inc.

Impact Therapeutics (shanghai), Inc

Xiaozhu Wang

Ye Edward Tian

Sui Xiong Cai

Lizhen Wu

Lijun Liu

Qingbing Xu

Guoxiang Wang

Yangzhen Jiang

Suixiong Cai

Feng Yin

Haijun Dong

Chengyun Gu

Xiuhua Hu

Sishun Kang

Shengzhi Chen

Qingli Bao

Zheng Meng

Xiuyan Zhang

Zhiqiang Dong

Compounds represented by Formula I in which A-A, R-R, L, Z and Q are defined herein. The compounds of Formula I are CHK 1 inhibitors. Therefore, the compounds can be used to treat diseases, disorders and conditions associated with continuous activation of CHK1 or with high internal DNA damage or injury during DNA replication, such as cancers.

3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof

The disclosure provides novel substituted fused heteroaromatic compounds as represented in Formula I, wherein A-Aand R-Rare defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inhibitors. Therefore, the compounds of the disclosure may be used to treat ATR-mediated diseases, disorders and conditions, such as cancer.

Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof

The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A-A, B-B, D-Dand R-Rare defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof

Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): 

1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof

Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R-Rare defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof

Disclosed are novel 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs thereof, represented by the Formula 1:  wherein Ar, A, R, R-Rare defined herein. Compounds having Formula I are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity, such as cancer.

1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof

Growing community of inventors

Jiangsu, China

Xiaozhu Wang